UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis

Annals of oncology, 2021-08, Vol.32 (8), p.983-993

2021

Volltextzugriff (PDF)

Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer

Annals of oncology, 2020-05, Vol.31 (5), p.582-589

2020

Volltextzugriff (PDF)

Breast cancer vaccines: maximizing cancer treatment by tapping into host immunity

Endocrine-related cancer, 2005-03, Vol.12 (1), p.1-17

2005

Volltextzugriff (PDF)

The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome

Breast cancer research and treatment, 2018-09, Vol.171 (2), p.273-282

2018

Volltextzugriff (PDF)

IMpassion130: Results from a global, randomised, double-blind, phase III study of atezolizumab (atezo) + nab-paclitaxel (nab-P) vs placebo + nab-P in treatment-naive, locally advanced or metastatic triple-negative breast cancer (mTNBC)

Annals of oncology, 2018-10, Vol.29, p.viii707-viii708

2018

Volltextzugriff (PDF)

Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice

Cancer research (Baltimore), 2001-05, Vol.61 (9), p.3689-3697

2001

Volltextzugriff (PDF)

Hepatocyte Nuclear Factor 1α is Expressed in a Hamster Insulinoma Line and Transactivates the Rat Insulin I Gene

Proceedings of the National Academy of Sciences - PNAS, 1992-08, Vol.89 (16), p.7300-7304

1992

Volltextzugriff (PDF)

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

The New England journal of medicine, 2018-11, Vol.379 (22), p.2108-2121

2018

Volltextzugriff (PDF)

The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors

Cancer research (Chicago, Ill.), 2001-02, Vol.61 (3), p.880-883

2001

Volltextzugriff (PDF)

Abstract MS1-2: MS1-2 Breast cancer immunotherapy: Building on clinical success

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.MS1-2-MS1-2

Emens, LA

2017

Volltextzugriff (PDF)

362PPatterns and predictors of first-line (1L) taxane use in US patients with metastatic triple-negative breast cancer (mTNBC)

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

Corrigendum to ‘First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis’: Annals of Oncology 2021; 32: 983-993

Annals of oncology, 2021-12, Vol.32 (12), p.1650-1650

2021

Volltextzugriff (PDF)

Safety, clinical activity and biomarkers of atezolizumab (atezo) in advanced ovarian cancer (OC)

Annals of oncology, 2016-10, Vol.27, p.vi300-vi300

2016

Volltextzugriff (PDF)

Corrigendum to ‘First-line atezolizumab plus nab-paclitaxel for unresectable locally advanced or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis’: Annals of Oncology 2021; volume 32: 983–993

Annals of oncology, 2021-10, Vol.32 (10), p.1308-1308

2021

Volltextzugriff (PDF)

305OOverall survival (OS) in KATE2, a phase II study of programmed death ligand 1 (PD-L1) inhibitor atezolizumab (atezo)+trastuzumab emtansine (T-DM1) vs placebo (pbo)+T-DM1 in previously treated HER2+ advanced breast cancer (BC)

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

Leveraging the activity of tumor vaccines with cytotoxic chemotherapy

Cancer research (Chicago, Ill.), 2005-09, Vol.65 (18), p.8059-8064

2005

Volltextzugriff (PDF)

LBA20Performance of PD-L1 immunohistochemistry (IHC) assays in unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): Post-hoc analysis of IMpassion130

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

Chemotherapy and tumor immunity: an unexpected collaboration

Frontiers in bioscience, 2008-01, Vol.13 (13), p.249

Emens, Leisha A

2008

Volltextzugriff (PDF)

LBA1_PRIMpassion130: Results from a global, randomised, double-blind, phase III study of atezolizumab (atezo) + nab-paclitaxel (nab-P) vs placebo + nab-P in treatment-naive, locally advanced or metastatic triple-negative breast cancer (mTNBC)

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response

The Journal of experimental medicine, 2005-05, Vol.201 (10), p.1591-1602

2005

Volltextzugriff (PDF)

Cost-effective manufacture of an allogeneic GM-CSF-secreting breast tumor vaccine in an academic cGMP facility

Cytotherapy (Oxford, England), 2005-03, Vol.7 (1), p.46-56

2005

Volltextzugriff (PDF)

Chemotherapy: friend or foe to cancer vaccines?

Current opinion in molecular therapeutics, 2001-02, Vol.3 (1), p.77

2001

Volltextzugriff (PDF)

Abstract OT2-06-04: MORPHEUS: A phase Ib/II trial platform evaluating the safety and efficacy of multiple cancer immunotherapy combinations in patients with hormone receptor–positive and triple-negative breast cancer

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.OT2-06-04-OT2-06-04

2019

Volltextzugriff (PDF)

Abstract PD3-01: Results from KATE2, a randomized phase 2 study of atezolizumab (atezo)+trastuzumab emtansine (T-DM1) vs placebo (pbo)+T-DM1 in previously treated HER2+ advanced breast cancer (BC)

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.PD3-01-PD3-01

2019

Volltextzugriff (PDF)

Abstract GS1-04: IMpassion130: Efficacy in immune biomarker subgroups from the global, randomized, double-blind, placebo-controlled, phase III study of atezolizumab + nab -paclitaxel in patients with treatment-naïve, locally advanced or metastatic triple-negative breast cancer

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.GS1-04-GS1-04

2019

Volltextzugriff (PDF)

1 – 25 von 112

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(106)
Mit Volltextzugriff
(104)

Publikationsform

Sprache

Englisch
(112)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis

Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer

Breast cancer vaccines: maximizing cancer treatment by tapping into host immunity

The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome

IMpassion130: Results from a global, randomised, double-blind, phase III study of atezolizumab (atezo) + nab-paclitaxel (nab-P) vs placebo + nab-P in treatment-naive, locally advanced or metastatic triple-negative breast cancer (mTNBC)

Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice

Hepatocyte Nuclear Factor 1α is Expressed in a Hamster Insulinoma Line and Transactivates the Rat Insulin I Gene

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors

Abstract MS1-2: MS1-2 Breast cancer immunotherapy: Building on clinical success

362PPatterns and predictors of first-line (1L) taxane use in US patients with metastatic triple-negative breast cancer (mTNBC)

Corrigendum to ‘First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis’: Annals of Oncology 2021; 32: 983-993

Safety, clinical activity and biomarkers of atezolizumab (atezo) in advanced ovarian cancer (OC)

Corrigendum to ‘First-line atezolizumab plus nab-paclitaxel for unresectable locally advanced or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis’: Annals of Oncology 2021; volume 32: 983–993

305OOverall survival (OS) in KATE2, a phase II study of programmed death ligand 1 (PD-L1) inhibitor atezolizumab (atezo)+trastuzumab emtansine (T-DM1) vs placebo (pbo)+T-DM1 in previously treated HER2+ advanced breast cancer (BC)

Leveraging the activity of tumor vaccines with cytotoxic chemotherapy

LBA20Performance of PD-L1 immunohistochemistry (IHC) assays in unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): Post-hoc analysis of IMpassion130

Chemotherapy and tumor immunity: an unexpected collaboration

LBA1_PRIMpassion130: Results from a global, randomised, double-blind, phase III study of atezolizumab (atezo) + nab-paclitaxel (nab-P) vs placebo + nab-P in treatment-naive, locally advanced or metastatic triple-negative breast cancer (mTNBC)

Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response

Cost-effective manufacture of an allogeneic GM-CSF-secreting breast tumor vaccine in an academic cGMP facility

Chemotherapy: friend or foe to cancer vaccines?

Abstract OT2-06-04: MORPHEUS: A phase Ib/II trial platform evaluating the safety and efficacy of multiple cancer immunotherapy combinations in patients with hormone receptor–positive and triple-negative breast cancer

Abstract PD3-01: Results from KATE2, a randomized phase 2 study of atezolizumab (atezo)+trastuzumab emtansine (T-DM1) vs placebo (pbo)+T-DM1 in previously treated HER2+ advanced breast cancer (BC)

Abstract GS1-04: IMpassion130: Efficacy in immune biomarker subgroups from the global, randomized, double-blind, placebo-controlled, phase III study of atezolizumab + nab -paclitaxel in patients with treatment-naïve, locally advanced or metastatic triple-negative breast cancer

Suchergebnisse filtern